Wright Medical Group N.V

Wright Medical — Merger or Acquisition (October 2014)

18 slides from Wright Medical's merger presentation, Oct 27, 2014

  1. Slide 1: Wright and Tornier: Creating the Premier High-Growth Extremities-Biologics Company

    Filed by Wright Medical Group, Inc. pursuant to Rule to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Wright Medical Group, Inc. Commission File No. 001-35823 Wright and Tornier Creating the Premier High-Grow

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,”“expect,” “plan,” “could,” “may,” “will,” “believe,”“estimate,” “forecast,”“goal,” “projec

  3. Slide 3: Note on Non-GAAP Financial Measures

    Note on Non-GAAP Financial Measures Wright and Tornier use non-GAAP financial measures, including EBITDA, as adjusted. Their respective management teams believe that the presentation of these measures provides useful information to investors and that these measures may assist investors in evaluating

  4. Slide 4: Important Additional Information and Where To Find It

    Important Additional Information and Where To Find It In connection with the proposed merger, Tornier plans to file with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 that will include a joint proxy statement of Wright and Tornier that also constitutes a pros

  5. Slide 5: Wright and Tornier Agree to Merge Creating Premier High-Growth Extremities-Biologics Company

    Today’s Announcement Wright and Tornier Agree to Merge Creating Premier High-Growth Extremities-Biologics Company Combination Will Offer Comprehensive Upper and Lower Extremity Product Portfolio and Broad Global Reach FurtherAcceleratesGrowth Opportunitiesin Threeof the FastestGrowingAreasin Orthopa

  6. Slide 6: Wright at a Glance

    Wright at a Glance Company Summary Recent Strategic Initiatives • Extremities-Biologics company with leadership position • Completed transformation to high growth Extremities- in in Lower Extremities -- foot & ankle Biologics pure play through successful divestiture of • NASDAQ: WMGI www.wmt.com Ort

  7. Slide 7: Augment Bone Graft is Approvable for Ankle and/or Hindfoot Fusion Indications

    Augment® Bone Graft is Approvable for Ankle and/or Hindfoot Fusion Indications First clinically proven, cost-effective alternative to autograft for ankle and/or hindfoot fusion indications Roughly a $300M U.S. Market Opportunity Final approval subject to customary preapproval inspections Unique solu

  8. Slide 8: Augment Accelerates Wright's Growth Opportunities

    Augment Accelerates Wright’s Growth Opportunities Demonstrated results Ankle Fusions Eliminates harvest site complications Patients avoid any Hindfoot Fusions donor site pain 8

  9. Slide 9: Tornier at a Glance

    Tornier at a Glance Company Summary Recent Strategic Initiatives • Extremities company with leadership position in Upper • Transitioned US Sales organization into separate Extremities --shoulder dedicated Upper and dedicated Lower Extremity reps, • NASDAQ: TRNX www.tornier.com including a significan

  10. Slide 10: Transaction Overview

    Transaction Overview • All stock transaction resulting in a combined equity value of approx. $3.3B – Combined company ownership: 52% Wright / 48% Tornier existing shareholders • For Tornier shareholders, exchange ratio implies a per share value for Tornier that represents a 28% premium to Tornier’s

  11. Slide 11: Compelling Strategic Rationale

    Compelling Strategic Rationale Creates the Premier High-Growth Extremities-Biologics Company with Comprehensive Upper and Lower Extremity Product Portfolio and Broad Global Reach • Natural, highly complementary fit of both businesses that retains pure-play extremities strategy • Combinedbusinesswill

  12. Slide 12: Compelling Strategic Rationale

    Compelling Strategic Rationale FurtherAcceleratesGrowthOpportunitiesin Threeof the FastestGrowingAreasin Orthopaedics • Combination provides Wright with access to large, upper extremities market with leadership position in shoulder • Opportunities for selling biologics across expanded upper and lowe

  13. Slide 13: Compelling Strategic Rationale

    Compelling Strategic Rationale Adds Significant Scale and Scope to Provide Accelerated Path to Profitability and Stronger Financial Profile Wright Sales ~$300M Tornier Sales ~$330M • Provides needed scale for both Upper businesses without diluting focus Upper Extremity 3% 10% Extremity Lower 5% 17%

  14. Slide 14: Benefits to Key Stakeholders

    Benefits to Key Stakeholders Customers • Significantly expands the breadth and depth of extremity products we offer surgical specialists • Combined products, sales and distribution talent, medical education and relationships will allow us to increase our focus on the needs of the surgeon specialists

  15. Slide 15: Corporate Structure

    Corporate Structure • Combinedcompanyto be called“Wright MedicalGroupN.V.” andanticipatestockwill continue to be NASDAQ listed and will continue to trade under ticker “WMGI” • Incorporated in the Netherlands • Tornier headquartered here for approximately 8 years • Best supports the growth strategy d

  16. Slide 16: Conclusion and Next Steps

    Conclusion and Next Steps Timing • Expected to close in the first half of 2015 Regulatory approvals • Subject to customary closing conditions, including HSR • Subject to Wright and Tornier shareholder approval Upcoming milestones • Wright third quarter 2014 earnings call scheduled for November 5, 20

  17. Slide 17: Creating Premier High-Growth Extremities-Biologics Company

    Creating Premier High-Growth Extremities-Biologics Company Comprehensive Upper and Lower Extremity Product Portfolio and Broad Global Reach Accelerated Growth Opportunities in Three of the Fastest Growing Areas in Orthopaedics Significant Scale & Scope to Provide Accelerated Path to Profitability an

  18. Slide 18: For additional information, please contact:

    For additional information, please contact: Julie Tracy Shawn McCormick Chief Communications Officer Chief Financial Officer julie.tracy@wmt.com shawn.mccormick@tornier.com (901) 290-5817 (952) 426-7646 www.wmt.com www.tornier.com NASDAQ: WMGI NASDAQ: TRNX 18

Wright Medical Group — Merger or Acquisition (October 2014) on 6ix